Purpose:
Immunotherapy (IT) and targeted therapy (TT) have improved survival for some patients with metastatic non-small cell lung cancer (NSCLC). Their lived experience is under-studied. We conducted a single centre, qualitative study to understand concerns and unmet needs amongst this novel survivor population.
Methods:
Eligible participants had metastatic NSCLC, aged >18, English-speaking and >6 months post initiation of IT/TT without progressive disease. Semi-structured interviews focused on physical, psychological, social and functional impacts of diagnosis, therapy and prognosis. Interviews were recorded and transcribed. Data were analysed via qualitative thematic analysis.
Results:
Between May and December 2019, 20 participants were interviewed: median age 62 (range 34-83), 13 (65%) female; median time since diagnosis of metastatic NSCLC 27 months (range 10-108). Twelve out of 20 (60%) participants had a targetable mutation (EGFR/ALK/BRAF); 6 were receiving IT, 11 TT, 2 IT + chemotherapy and 1 IT + TT. Four main themes were identified: living long-term on IT and TT (chronic toxicities), psychological concerns (living with uncertainty, fear of cancer progression, scan-related anxiety), support with practical issues (finances, employment amidst prognostic uncertainty, challenges with trial participation) and wanting information pertinent to NSCLC subtype.
Conclusions:
Longer-term survivors of metastatic NSCLC experience significant physical, psychological and functional concerns and unmet needs. Results will inform a broader cross-sectional survey and resources to address the needs of this growing survivor group.
Implications For Cancer Survivors:
A 'one-size-fits-all' approach to NSCLC survivorship is no longer appropriate. Survivors of metastatic NSCLC treated with novel therapies may benefit from specific information regarding long-term toxicities and psychological supports.
Citing Articles
Feasibility of a nurse-initiated brief cognitive behavioral strategy intervention program for symptom clusters experienced by patients with advanced non-small cell lung cancer.
Hamada T, Ishikawa H, Rosenzweig M, Nishimura N, Sakakibara-Konishi J, Itoh T
Asia Pac J Oncol Nurs. 2024; 11(11):100600.
PMID: 39655228
PMC: 11626806.
DOI: 10.1016/j.apjon.2024.100600.
Perspectives of patients, partners, primary and hospital-based health care professionals on living with advanced cancer and systemic treatment.
Kolsteren E, Deuning-Smit E, Prins J, van der Graaf W, Kwakkenbos L, Custers J
J Cancer Surviv. 2024; .
PMID: 39470942
DOI: 10.1007/s11764-024-01698-w.
Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis.
Andersen J, Johansen J, Urbanska E, Meldgaard P, Hjorth-Hansen P, Kristiansen C
Lung Cancer Manag. 2024; 13(1):LMT68.
PMID: 38818369
PMC: 11137781.
DOI: 10.2217/lmt-2023-0013.
Carrying on with life as a lung cancer survivor: a qualitative study of Australian survivors' employment, finances, relationships, and healthcare experiences.
Laidsaar-Powell R, Butow P, Brown B, Mander K, Young J, Stone E
Transl Lung Cancer Res. 2024; 13(4):785-798.
PMID: 38736502
PMC: 11082701.
DOI: 10.21037/tlcr-23-815.
Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study.
Vanlaer N, Dirven I, Neyns B, Rogiers A
Cancers (Basel). 2024; 16(9).
PMID: 38730590
PMC: 11083145.
DOI: 10.3390/cancers16091638.
What patients with advanced cancer experience as helpful in navigating their life with a long-term response: a qualitative study.
Zwanenburg L, van der Lee M, Koldenhof J, Suijkerbuijk K, Schellekens M
Support Care Cancer. 2024; 32(4):222.
PMID: 38470541
PMC: 10933145.
DOI: 10.1007/s00520-024-08398-2.
Content Quality of YouTube Videos About Metastatic Breast Cancer in Young Women: Systematic Assessment.
Morena N, Ahisar Y, Wang X, Nguyen D, Rentschler C, Meguerditchian A
JMIR Cancer. 2023; 9:e45101.
PMID: 37737837
PMC: 10685279.
DOI: 10.2196/45101.
Evaluation of Managing Cancer and Living Meaningfully (CALM) in people with advanced non-small cell lung cancer treated with immunotherapies or targeted therapies: protocol for a single-arm, mixed-methods pilot study.
Lynch F, Rodin G, Jefford M, Duffy M, Lai-Kwon J, Heynemann S
BMJ Open. 2023; 13(7):e072322.
PMID: 37524546
PMC: 10391815.
DOI: 10.1136/bmjopen-2023-072322.
Application of a revised model for coping with advanced cancer to qualitatively explore lung cancer survivors' experiences of ongoing physical effects, novel treatments, uncertainty, and coping.
Laidsaar-Powell R, Butow P, Brown B, Mander K, Young J, Stone E
J Cancer Surviv. 2023; 18(6):1754-1770.
PMID: 37495907
PMC: 11502627.
DOI: 10.1007/s11764-023-01417-x.
Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study.
Wen M, Hsu H, Chang C, Wang J, Kuo C, Hsin Y
PLoS One. 2023; 18(5):e0286333.
PMID: 37252908
PMC: 10228791.
DOI: 10.1371/journal.pone.0286333.
Scanxiety Conversations on Twitter: Observational Study.
Bui K, Li Z, Dhillon H, Kiely B, Blinman P
JMIR Cancer. 2023; 9:e43609.
PMID: 37074770
PMC: 10157462.
DOI: 10.2196/43609.
Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.
Derry-Vick H, Heathcote L, Glesby N, Stribling J, Luebke M, Epstein A
Cancers (Basel). 2023; 15(5).
PMID: 36900174
PMC: 10000102.
DOI: 10.3390/cancers15051381.
Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapy.
Zwanenburg L, Suijkerbuijk K, van Dongen S, Koldenhof J, van Roozendaal A, van der Lee M
J Cancer Surviv. 2022; 18(3):750-760.
PMID: 36495465
PMC: 11082039.
DOI: 10.1007/s11764-022-01306-9.
Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review.
Kolsteren E, Deuning-Smit E, Chu A, van der Hoeven Y, Prins J, van der Graaf W
Cancers (Basel). 2022; 14(16).
PMID: 36010883
PMC: 9405683.
DOI: 10.3390/cancers14163889.
